RSNA 2021 Molecular Imaging Preview

FDG-PET/CT scans assessed for clinical utility in COVID-19

By Will Morton, staff writer

Monday, November 29 | 9:30 a.m.-10:30 a.m. | SSNMMI03-4 | Room S402
In this talk, researchers will present a study to determine imaging findings and the potential clinical utility of FDG-PET/CT in patients with laboratory-confirmed COVID-19. They suggest FDG-PET/CT scans could be helpful in predicting disease severity.

Nuclear medicine specialist Dr. Rick Wray and colleagues at Memorial Sloan Kettering Cancer Center performed a retrospective review of patients diagnosed with COVID-19 who had FDG-PET/CT scans for routine cancer care between March 1, 2020, and April 30, 2020, during the height of the pandemic in New York City. They reviewed the PET/CT scans for findings suspicious for COVID-19 and noted location, FDG avidity (maximum standardized uptake value [SUVmax]), CT morphology, and time interval between PET/CT and reverse transcription polymerase chain reaction (RT-PCR).

Thirteen out of 31 patients had positive PET/CT scans, yielding a detection rate of 41.9%, the researchers found. Patients with positive scans had significantly higher rates of symptomatic COVID-19 infection (77% vs. 28%, p = 0.01) and hospitalizations (46% vs. 0%, p = 0.002) compared with patients with negative scans.

Eleven of those 13 patients (84.6%) with positive scans had FDG-avid lung findings, with mean lung SUVmax of 5.36. However, lung SUVmax was not associated with COVID-19 symptoms, severity, or disease course, the researchers found.

Ultimately, FDG-PET/CT has limited sensitivity for detecting COVID-19 infection, yet positive PET scans were associated with higher risk of symptomatic infection and hospitalizations, Wray and colleagues wrote.

Check out this Monday morning presentation to learn more.

Last Updated np 11/19/2021 11:42:22 AM